Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...

Vertex Pharmaceuticals ... Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals Inc. notched two FDA victories ... for its drugs and likely boosting its own future revenue. The Boston-based drugmaker heard back from the FDA ahead of its scheduled ...

(Reuters) -Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a placebo in reducing pain ...

Vertex Pharmaceuticals said Thursday that its closely watched drug, suzetrigine, reduced pain compared to baseline but did not outperform a placebo in a Phase 2 study, raising doubts about the ...

M.D. Ph.D., 50 Northern Ave, Boston, Massachusetts 02210, Chief Scientific Officer, Executive Vice President, Global Research Vertex Pharmaceuticals Incorporated ...